Stock Idea - Network 18 Fincap

Recommendation: Buy

CMP = Rs 411

Price target: Rs 651

Key points:

·          After the transfer of Studio18’s business to Viacom18, Network18 has filed the amended draft offer document for its rights issue. The old draft document stated the earlier objects of the issue to raise a part of the funds for film projects under Studio18. I maintain my valuation of the right issue at Rs 133.6 per share.

·          Network18 proposes to use a part of the rights issue proceeds towards capex on television content production. We believe, the investment in content production business will cater to the content requirements of the forthcoming channels of Viacom18.

·          HomeShop18 is going great guns with business spreading over 2000 towns & cities across India, and with average sales of approximately 20 lakh per day just a few months after its launch. A full-fledged home shopping channel is in the offing.

·          Issue of preferential warrants in TV18 and GBN will lead to increase in Network18’s holding in TV18 to 53.3% and in GBN to 45.1%.

·          I maintain Buy recommendation on the stock with price target of Rs 651.

Stock Idea - Ahmednagar Forgings

Recommendation: Buy

CMP = Rs 222 (as of Thursday)

Price target: Rs 300

Key points:

·          Ahmednagar Forgings Ltd (AFL), a subsidiary of Amtek Auto, manufactures small- and medium-sized forged components such as connecting rods, gear blanks, shafts, transmission components, flanges and hubs. AFL is a tier-1 supplier to large domestic original equipment manufacturers (OEMs) like Tata Motors, Ashok Leyland, Eicher Motors, Force Motors, Bajaj Auto and Maruti Suzuki.

·          In Q4FY2007 AFL’s sales grew by 52.7% to Rs 150.7 crore, which was below our expectations. The profit after tax (PAT) grew by 61.9% to Rs 16.6 crore in the same quarter. The profit growth was lower mainly due to the slowdown in the domestic market and the impact of the strengthening rupee on its exports. 

·          For the fiscal ended June 2007, the company has reported a 59.9% growth in its net sales to Rs 600.3 crore and a 75.3% growth in its net profit to Rs 68.2 crore against expected Rs 67.5 crore of PAT.

·          Though the company has a strong order book, I would like to take a cautious view on the domestic sales in FY2008 in light of the slowdown in the OEM segment. The outlook on the exports remains bullish with the commencement of the additional lines and increase in the utilisation levels. However, the margins may be hit due to rupee appreciation as around 40% of its exports are in US dollar terms.

·          Considering the slowdown in the domestic market and the delay in commencement of the export lines, I am downgrading the FY2008 EPS estimate by 30% from Rs 36.5 to Rs 25.3 and am estimate EPS for FY2009 at Rs 32.2.

·          At the current market price of Rs222, the stock trades at attractive valuations of 6.9x its FY2009E earnings and an enterprise value (EV)/earnings before interest, depreciation, tax and amortisation (EBIDTA) of 4.4x. I maintain Buy recommendation on the stock with a price target of Rs 300.

Stock Idea - Torrent Pharmaceuticals

Recommendation: Buy

CMP = Rs 185

Price target: Rs 260

Key points

·          Strong domestic formulation business: Torrent Pharmaceuticals (Torrent) is a well-known name in the branded formulation market in India, with a strong focus on the fast growing chronic lifestyle segments. I believe Torrent's domestic formulation business will continue to grow at above-average industry rate of 17.5% CAGR over FY2007-09 on the back of aggressive new products and increased geographical penetration.

·          Investment phase in Brazil and Russia is over: Torrent's operations in Brazil and Russia turned around in FY2007. The company is expanding into newer markets in these regions. With the investment phase now over, these businesses should start contributing to Torrent's profitability from FY2008 onwards. 

·          US foray in FY2009: Torrent has filed seven ANDAs and five DMFs in the USA. It expects to make additional 14 ANDA and nine DMF filings in FY2008. Even though the company is confident of starting its US business in early FY2009, I have not factored in any upside as the marketing arrangements for the products have not yet been finalised. 

·          Compelling valuations; upside of 40%: I expect Torrent's earnings to grow at a 29.7% CAGR to Rs 157.4 crore in FY2009 on the back of a 14.8% growth in revenues and a 270-basis-point expansion in the margin. At the current market price of Rs 185, the stock is quoting at 13.0x its FY2008E earnings of Rs 14.2 and 9.9x its FY2009E earnings of Rs 18.6.

·          I recommend Buy option for Torrent with a one-year price target of Rs 260.

Stock Idea - Apollo Tyres

Recommendation: Buy

CMP = Rs 39

Price target: Rs 47

Key points:

·          A strong demand for tyre replacement in the commercial vehicle (CV) segment is triggering a healthy growth for Apollo Tyres, which is the market leader in this segment.

·          I expect Apollo Tyres to be one of the top performers in the coming Q2FY2008 results. I expect the revenues of the company to grow by 8.5% and the profit to rise by 99.4% for the forthcoming quarter.

·          With improved performance of its subsidiary Dunlop as a result of better utilisation, price hikes and debt restructuring the consolidated picture for the company looks even better. 

·          I maintain positive outlook on the company considering strong growth potential and sustainable margins. I am revising upwards the earnings estimates for the company by 5.3% for FY2008 and by 10.5% for FY2009.

·          I maintain Buy recommendation on the stock with a price target of Rs 47.

Stock Idea - Shiv-Vani Oil & Gas Exploration Services

Recommendation: Buy

Price target: Rs 480

Current market price: Rs 370

Key points

·          Largest player in onshore drilling and seismic survey services: With a fleet of 25 onshore drilling rigs and six seismic survey crew, Shiv-Vani Oil & Gas Exploration (SOGEL) has emerged as the largest onshore service provider catering to the needs of oil and gas exploration companies. The augmentation of assets by the company is well timed in the industry upcycle. The heightened exploration activity has resulted in severe shortage of resources with service providers, leading to firming up of day rates (or billing rates per km in case of seismic survey) for various services. 

·          Healthy order book provides growth visibility: In addition to the favourable business environment, the existing order backlog of Rs 2,950 crore itself provides a strong revenue growth visibility over the next two years. Almost 70% of the order backlog (excluding the Oman order) is executable over the next 24-30 months. The company also has a healthy order pipeline with planned bids worth over Rs 5,000 crore for global tenders over the next few quarters.

·          Margins to improve: SOGEL has reported a healthy operating profit margin (OPM) of 35% in CY2006, which is expected to improve by 300 basis points to 38% by CY2009. The improvement in its OPM would be driven by higher realisation (day rates or billing rates per km) and more efficient utilisation of its assets. 

·          Attractive valuation: The consolidated revenues and earnings are expected to grow at compounded annual growth rate (CAGR) of 60.3% and 72.7% respectively, over the three-year period CY2006-09. Despite the robust growth prospects, the stock is available at attractive valuations of 11.3x CY2008 and 8.5x CY2009 earnings estimates.

·          I recommend Buy call on the stock with a price target of Rs 480.

Stock Idea - Kamat Hotels

Recommendation: Buy

CMP: Rs 175

Target price : Rs 225

Key points:

·          Kamat Hotels plans to almost double its owned room count, from current 467 to 907, by FY10. Its advent into management of 1045 rooms by FY09 would catapult it in the league of the front runners in hospitality business with a diversified portfolio covering locations in metro as well as tier II cities. This expansion would lend a growth of 22% to its revenues and at current valuations make the stock a compelling BUY.

·          Room base to quadruple by FY09:

Kamat Hotel has plans to expand its chain to tier II cities which are on growth path with favourable government policies and private sector focus. The current room base of 467 is expected to increase to 777 by FY09 effecting a 22% surge in revenues. Kamat Hotels plans to foray into management contracts of hotels; this step would help it to remain asset light along with better visibility of its brands. I expect pre-tax revenues arising from management contracts at Rs 3.86 crore in FY09 contributing directly to the bottom line.

·          Locational benefit:

The Orchid & Lotus Suites, Kamat Hotel’s two money spinners are strategically located near the Mumbai domestic and international airports respectively. The prime locations result in envious occupancy rates across the year for both the properties.

·          Business strategy:

Kamat Hotel follows the business strategy of charging average room rates (ARR) a tad lower to its competition, while capitalising on the occupancy rates throughout the year. This strategy augurs well for the company as they record operating margins at 46.7% in FY07, one of the highest in the sector. We expect Kamat Hotels to follow the same trajectory of high occupancies and higher margins in future.

·          Time Frame: 12-15 months, with a price target of Rs 225.

Stock Idea - Ranbaxy Laboratories

Recommendation: Buy

CMP = Rs 439

Price target: Rs 500

Key points

·          Ranbaxy Laboratories (Ranbaxy) is increasing its stake in Zenotech Laboratories (Zenotech) from 7% currently to 45% at a price of Rs 160 per share, resulting into a total investment of Rs 214 crore. The above increase in stake in Zenotech to 45% will trigger a mandatory open offer by Ranbaxy to other shareholders of Zenotech, at a price of Rs 160 per share or as determined by the Securities and Exchange Board of India (SEBI) regulation.

·          Zenotech is a Hyderabad-based research driven pharmaceutical company that develops new biological entities in the areas of cancer and neurology. The company currently has a portfolio of ten oncology injectables and five anesthesiology injectables developed and marketed in India. Zenotech also has an existing agreement with Ranbaxy for developing and marketing 14 injectables (Abbreviated New Drug Applications [ANDAs]) including seven in oncology in the US and Canada. 

·          By increasing its stake in Zenotech, Ranbaxy is preparing to capitalise the huge opportunity that awaits pharmaceutical companies in the field of biologics and oncology. The opening up of biosimilars or biogenerics in the regulated markets of the USA and Europe further enhances the attractiveness of this segment. Ranbaxy aims to enter the European Union biologics market through this acquisition by end of 2010-11. With the Zenotech acquisition, Ranbaxy plans to file seven ANDAs in the oncology segment for the US market in the coming months.

·          As per media reports, Ranbaxy is in advanced stages of negotiation with numerous private equity players to hive off its new chemical entity (NCE) research division into a separate entity by 2008. Ranbaxy's current pipeline consists of two molecules in the clinics and another six-seven molecules in the pre-clinical stages. The demerger of the NCE division will unlock value for investors, generate new funding options for discovery research and de-risk the company's main generic business. 

·          I maintain positive outlook on Ranbaxy and feel that it is among the best placed companies to leverage the global generic opportunity with its extremely diversified business model and a large product portfolio.

·          At the current market price of Rs 439, Ranbaxy is trading at 23.7x its estimated CY2007 and 24.8x its estimated CY2008 earnings. I maintain Buy recommendation on the stock with a revised price target of Rs 500.

 

© blogger templates 3 column | Make Money Online